We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 29, 2020

A Dose-Dense Short-Term Therapy for HIV/AIDS Patients With High-Risk Burkitt Lymphoma or High-Grade B-Cell Lymphoma

British Journal of Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Haematology
A Dose-Dense Short-Term Therapy for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients With High-Risk Burkitt Lymphoma or High-Grade B-Cell Lymphoma: Safety and Efficacy Results of the "CARMEN" Phase II Trial
Br. J. Haematol 2020 Oct 21;[EPub Ahead of Print], AJM Ferreri, C Cattaneo, A Lleshi, L Verga, B Allione, F Facchetti, M Ponzoni, M Foppoli, D Ferrari, L Rigacci, L Pecciarini, G Donadoni, L Fumagalli, M Sassone, T Calimeri, G Rossi, M Spina, A Re

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading